VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2020

Feb 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2020-02-17

Reporting Person: Tatsis Ourania (SVP, CRO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-17	Common Stock	F	597	$241.50	Disposed	16349	Direct
2020-02-18	Common Stock	S	160	$241.82	Disposed	16189	Direct
2020-02-18	Common Stock	S	528	$242.78	Disposed	15661	Direct
2020-02-18	Common Stock	S	160	$243.78	Disposed	15501	Direct
2020-02-18	Common Stock	S	286	$244.99	Disposed	15215	Direct
2020-02-18	Common Stock	S	145	$245.75	Disposed	15070	Direct

Footnotes

F1: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $241.82 (range $241.33 to $242.18).

F3: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $242.78 (range $242.38 to $243.31).

F5: Open market sales reported on this line occurred at a weighted average price of $243.78 (range $243.42 to $244.23).

F6: Open market sales reported on this line occurred at a weighted average price of $244.99 (range $244.52 to $245.30).

F7: Open market sales reported on this line occurred at a weighted average price of $245.75 (range $245.54 to $245.85).